Visit us at EHA
Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at www.oncopeptides-us.com
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our German operations at www.oncopeptides.de
Change Language
Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.